CASE REPORT

Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies

Giovannella Palmieri, Carlo Buonerba, Piera Federico, Luigi Formisano, Lucia Nappi, Giuseppe Di Lorenzo, Mirella Marino, Vincenzo Damiano

Giovannella Palmieri, Carlo Buonerba, Piera Federico, Luigi Formisano, Lucia Nappi, Giuseppe Di Lorenzo, Mirella Marino, Vincenzo Damiano, Dipartimento di Endocrinologia ed Oncologia Clinica e Molecolare, Università Federico II, 80131 Napoli, Italy
Giovannella Palmieri, Giuseppe Di Lorenzo, Vincenzo Damiano, Centro Regionale Tumori Rari (Regional Center for Rare Tumors), University Federico II, 80128 Naples, Italy
Mirella Marino, Department of Pathology, Regina Elena National Cancer Institute, 00144 Rome, Italy

Author contributions: Palmieri G and Damiano V originally conceived the treatment; Buonerba C drafted the manuscript; Palmieri G, Buonerba C and Di Lorenzo G critically revised the manuscript; Palmieri G, Buonerba C, Federico P, Formisano L, Nappi L, and Damiano V followed up the patients; Marino M performed additional histological examinations of tumor samples.

Correspondence to: Giovannella Palmieri, PhD, Molecular and Clinical Endocrinology and Oncology Department, University Federico II, Via Pansini 5, 80128 Naples, Italy. giovpalm@unina.it
Telephone: +39-817462114 Fax: +39-817462114
Received: March 5, 2012 Revised: June 19, 2012
Accepted: June 30, 2012
Published online: July 10, 2012

Abstract

Although thymic epithelial tumors (TETs) are rare in the general population, they represent the most frequently diagnosed primary malignant tumor of the anterior mediastinum. Unlike localized disease, metastatic disease is invariably fatal. While several chemotherapy agents have proven to be effective in TETs, somatostatin analogs are the only targeted agents with an established role in this disease. Everolimus is an mTOR inhibitor with multiple application in oncology. In this report, we show for the first time that everolimus was effective in two heavily pretreated patients with advanced TETs, with a progression-free survival longer than 1 year and minimal toxicity.

© 2012 Baishideng. All rights reserved.

Key words: Thymoma; Everolimus; mTOR; Mediastinum; Target

Peer reviewer: Robert Mandic, MD, Associate Professor, Head of Research Laboratory, Department of Otolaryngology, Head and Neck Surgery, University Hospital Giessen and Marburg, Campus Marburg, Deutschhausstrasse 3, D-35037 Marburg, Germany

Palmieri G, Buonerba C, Federico P, Formisano L, Nappi L, Di Lorenzo G, Marino M, Damiano V. Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies.

World J Clin Oncol 2012; 3(7): 111-115 Available from: URL: http://www.wjgnet.com/2218-4333/full/v3/i7/111.htm DOI: http://dx.doi.org/10.5306/wjco.v3.i7.111

INTRODUCTION

Thymic epithelial tumors (TETs) are rare in the general population, with an estimated incidence in Netherlands of 3.2 cases per 1 000 000 inhabitants[1]. In spite of their rarity, TETs are the most frequently diagnosed primary malignant tumor of the anterior mediastinum, accounting for about 40% of mediastinal masses in adult patients[2]. Stage and histology are predictive of survival[3]. At histological examination, TETs present both epithelial and lymphocytic cells. Epithelial cells are responsible for neoplastic growth and can regulate maturation of the accompanying lymphocytic population, which is involved in the typical associated autoimmune syndromes[4]. Surgery, radiotherapy, and chemotherapy offer a possibility of cure for patients with localized or locally advanced TETs. Metastatic disease is virtually incurable but highly responsive to chemotherapy, which can significantly prolong survival and palliate symptoms. TETs are responsive to several anti-neoplastic agents including platinum.
compounds, anthracyclines, and pyrimidine analogs. Among targeted drugs, somatostatin analogs, employed in combination with prednisone, provided radiological disease stabilization in TETs patients and improvement of the associated auto-immune syndromes.

The biology of TETs is presently unknown. Immunohistochemistry data showing expression of c-KIT and epidermal growth factor receptor (EGFR) in TETs prompted experimentation of imatinib and cetuximab in TETs. Multi tyrosine kinases inhibitors (such as sorafenib and sunitinib) and histone deacetylase inhibitors (such as bolinostat) were also tested in TETs. Unfortunately, results obtained with targeted therapy, with the exception of somatostatin analogues, were generally modest and can presently be considered inconclusive and not applicable to clinical practice.

Everolimus (Afinitor®, Novartis Pharma, Basel, Switzerland) is an oral inhibitor of the mTOR pathway with multiple applications in transplantation medicine, cardiology and oncology. In two phase III randomized, placebo-controlled trials, everolimus, administered at 10 mg daily, successfully prolonged progression free survival in patients with advanced kidney cancer and neuroendocrine pancreatic cancer. Of all retrospectively reviewed patients treated for advanced TETs at our Institution in the last five years, records of two cases who received everolimus were identified. Everolimus was obtained for compassionate use with approval of the local ethics committee on the grounds of its broad range of antitumor activity and in view of lack of medical options of established efficacy. Both patients gave their informed consent to treatment. Although they had been heavily pretreated, they obtained a remarkable, long-lasting clinical improvement with everolimus, with improved quality of life, a durable radiographic response and manageable side effects, as detailed below.

**CASE REPORT**

**Case 1**

In October 2005, the patient, a 51-year old woman from Genua, with no relevant medical history, was incidentally diagnosed with a mediastinal mass on chest X-ray. A chest computed tomography scan with contrast showed the presence of a 6 cm mass in the upper-anterior mediastinum, with multiple bilateral pleural metastases. An ultrasound-guided trans-thoracic core biopsy was performed at the “Gallino” Hospital of Genua. Histologic analysis was diagnostic of B2 thymic epithelial tumor (World Health Organization 2004). Additional histologic analyses, performed at the Department of Pathology of Regina Elena (Rome), revealed strong EGFR expression on immunohistochemistry. An 111In-DTPA-pentetreotide scintigraphy (Octreoscan) showed intense radioactivity uptake in the mediastinal and pleural lesions.

Patient was completely asymptomatic at the time of the diagnosis, with an Eastern Cooperative Oncology Group performance status of 0. In view of the advanced stage of the disease (stage IV according to the Masaoka staging system), patient was judged to be inoperable and suitable for medical therapy. Since November 2005 to August 2010, patient underwent several lines of treatment, which included cisplatin-doxorubicin-cyclophosphamide, carboplatin-etoposide, capectabine-gemcitabine and cisplatin-doxorubicin-cyclophosphamide-prednisone. Patient also received single agent cetuximab, single agent imatinib, high dose prednisone and single agent octreotide. Patient received all of these anti-neoplastic regimens at the medical Oncology Department of the “Gallino” Hospital (Genua), except for imatinib, which was delivered at the Department of Molecular and Clinical Oncology and Endocrinology of University Federico II of Naples. Since January 2005 to the present time, patient has uninterruptedly received long-acting somatostatin analogs (octreotide LAR 30 mg or lanreotide LAR 60 mg delivered intramuscularly every month). No unexpected or life-threatening side effects were reported. Heart, liver, kidney and bone marrow functions were periodically monitored during treatment administration. Due to intolerance to iodine contrast, treatment response was periodically evaluated with PET-TAC with FDG, without contrast, approximately every three-four months while receiving treatment and every 6 mo during follow-up. In August 2010, patient had complained about mild dyspnea at rest for the past month which worsened on exertion. Her Eastern Cooperative Oncology Group performance status was 1. With respect to her last scan performed in April 2010, positron emission tomographic/computed tomographic (PET-CT) scan performed in July 2010 showed increased size and SUV of the mediastinal mass (SUVmax = 6.3 vs 4.5) and of the bilateral pleural lesions (SUVmax = 4.5 vs 3.5). Given the amount of chemotherapy received, patient was no longer considered suitable for cytotoxic therapy. She was started on everolimus on August 4, 2010 at the dose of 5 mg/d, which was increased to 10 mg/d after a week. Follow-up during treatment was performed with a complete blood count every two weeks and a complete blood chemistry every month, history and physical examination every two months, with phone contact at need, PET-CT scan approximately every three months, as well as ecocardiographic assessment of heart function every 6 mo.

After two weeks’ treatment, patient developed grade 2 oral mucositis with thrush, which resolved with appropriate antifungal and coating agents. Patient also developed grade 1 hyperglycemia, which was easily managed with diet recommendations. After two months’ treatment, patient referred a marked improvement of dyspnea. Her performance status had improved to 0. On October 25th, 2010 patient underwent a PET-CT scan, which showed disappearance of pleural effusion and decreased SUV of all pathologic lesions (Figure 1). Patient underwent subsequent scans in January 2011, May 2011 and August 2011 which indicated lack of progression and progressive decrease in the metabolic activity of the lesions. During treatment with everolimus, patient has...
July 10, 2012  Volume 3  Issue 7  113

Palmieri G et al. Everolimus in thymic epithelial malignancies

reported several episodes grade 1/2 diarrhea, stomatitis, anemia, rash, hypertension. All of these side effects were manageable and were responsible for a total treatment interruption of 7 wk. Dose was never reduced throughout treatment. As of November 30th, 2011 patient has been continuing to take 10 mg everolimus daily, with complete resolution of dyspnea and a performance status of 0.

Case 2
In January 2007, the patient, a 42-year old woman from Naples, complaining of severe tiredness and showing palpebral ptosis, was referred a neurologist for suspected myasthenia gravis. Diagnosis was confirmed by electromyography and serum anti-acetylcholinesterase antibodies levels and patient was started on pyridostigmine. A whole body CT scan with and without contrast showed a mediastinal mass (4.2 cm × 6.5 cm), which extended from the right paratracheal space to the aorto-pulmonary window and was attached to the esophagus and the left atrium. A pericardial effusion was detected along with multiple pleural lesions (largest diameter, 27 mm × 38 mm). Patient subsequently received everolimus, according to the same dosing and schedule adopted for case 1. After one month’s treatment pyridostigmine dose was slowly tapered and was suspended after three months. A CT scan was scheduled for October 2011, but a subsequent CT scan was performed in February 2011, due to patient’s poor compliance. Stable disease was achieved, with the mediastinal mass measuring 18 mm × 51 mm, shrinkage of the largest pleural metastasis, which measured 16 mm × 9 mm, and shrinkage or stability of the others. Subsequent CT scans performed in June and November 2011 confirmed stable disease. As of November 30th, 2011 patient is free of progression and continuing treatment with everolimus.

DISCUSSION
Platinum-based chemotherapy is the standard approach for TETs not amenable to loco-regional treatments. Cisplatin-doxorubicin-cyclophosphamide[13], cisplatin-etoposide[13] and carboplatin-paclitaxel[14] are among the combination regimens tested as first-line treatment for thymomas, with a response rate of 42.9%-56% and a PFS of 16.7-26.4 mo. Poor evidence about second-line treatment is available in literature. We showed that combination of capcitabine and gemcitabine was able to provide a PFS of 11 mo (95% confidence interval 4-17), with an overall response rate of 40% and excellent tolerance in cisplatin-pretreated patients[15]. Single-agent pemetrexed also provided a promising PFS of 45.4 wk in patients with previously treated thymoma[16].

Somatostatin analogues, employed either alone or in combination with prednisone, were the first targeted agents to prove to be active in TETs[17], with a PFS of 9.2 mo (95% CI, 8.1 mo to 13.9 mo), obtained with the combination regimen in a phase II trial[18]. Although several other targeted agents, including cetuximab, cixutumumab, sorafenib and sunitinib, yielded promising results in TETs...
in either single cases or small series, no conclusive evidence is presently available for any of these drugs. Of note, one of the largest phase II trial on targeted agents was conducted on hystone deacetylase inhibitor belinostat in 25 thymoma patients, with a response rate of 8% only, but a promising TTP of 11.4 mo. The mTOR pathway plays a critical role for neoplastic growth via phosphorylation of the p70 S6 kinase, a key enzyme in protein synthesis, and it is also implicated in regulation of actin cytoskeleton, angiogenesis and cellular response to hypoxia and energy depletion. Both of these soluble factors may have a role in TETs biology. In fact, a retrospective analysis of 111 histology samples showed that 22 cases (20%) were positive for IGF-1R on immunohistochemistry. Similarly, EGFR was detected in 23 of 31 of TETs on immunohistochemistry. Conversely, anti-IGF-1R antibody cixutumumab and anti-EGFR antibody cetuximab demonstrated activity in TETs. Although unsupported by in vitro experiences, these findings suggest that stimuli transduced by TK receptors, and consequently by mTOR, are important for thymoma growth, thus providing the biological rationale to support the use of everolimus in TETs. Of note, investigational mTOR inhibitor ridaforolimus recently provided a prolonged disease stabilization (> 16 wk) in a patient with thymic carcinoma in a phase 1 trial.

The two cases reported here present several interesting points worthy of discussion. First, the PFS longer than one year and the incontrovertible and marked improvement of clinical conditions and quality of life obtained in both of these two patients strongly suggest that everolimus merits additional clinical investigations in TETs patients. Furthermore, as cixutumumab may increase signaling via the mTOR pathway, experimentation of the combination of everolimus plus cixutumumab appears to be of interest. Second, patient 2 also showed remission of myasthenia gravis, and pyridostigmine could be suspended. Such effect may be due to the immune-suppressant properties of everolimus coupled with its anti-tumor efficacy. Third, patient 1 was evaluated with PET/CT without iodine contrast during treatment with everolimus and decrease in FDG uptake as shown in Figure 1 was concordant with clinical benefit. We previously reported that PET results were concordant results of CT scans with iodine contrast in 6 of 9 patients for whom both examinations were performed in the TET-MAX trial. PET/CT could be useful for evaluation of response in TETs, but additional data are required.

In conclusion, these two are the first reported cases of everolimus in patients with TETs. We believe that the prolonged clinical benefit shown in these patients should encourage experimentation of everolimus in this disease, either alone or in combination with other promising agents, such as cixutumumab.

REFERENCES

1. de Jong WK, Blauuwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008; 44:123-130
2. Cameron RB, Loehrer PJ, Thomas CR Jr. Neoplasms of the mediastinum. In: DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology (ed 6). Philadelphia, PA: Lippincott-Raven; 2001:1019-1036
3. Margaritora S, Cesarino A, Cusumano G, Meacci E, D’Angelillo R, Bonassi S, Carmassale G, Porziella V, Tessitore A, Vita ML, Lauriola L, Evoli A, Granone F. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg 2010; 89:245-52; discussion 252
4. Okumura M, Fujiy H, Shiono H, Inoue M, Minami M, Utsumi T, Kadota Y, Sawa Y. Immunological function of thymus and pathogenesis of paraneoplastic myasthenia gravis. Gen Thoric Cardiovasc Surg 2008; 36:143-150
5. Schmitt J, Loehrer PJ. The role of chemotherapy in advanced thymoma. J Thorac Oncol 2010; 5:S357-S360
6. Palmieri G, Merola G, Federico P, Petillo L, Marino M, Lalle M, Miliea M, Ceribelli A, Montella L, Merola C, Del Prete S, Bergaglio M, De Placido S, Di Lorenzo G. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumours (TETs). Ann Oncol 2010; 21:1168-1172
7. Loehrer PJ, Wang W, Johnson DH, Aisner SC, Ettinger DS. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 2004; 22:293-299
8. Palmieri G, Marino M, Buonerba C, Federico P, Conti S, Miliea M, Petillo L, Evoli A, Lalle M, Ceribelli A, Merola G, Manato E, Sioletic S, De Placido S, Di Lorenzo G, Damiano V. Imatinib mesylate in thymic epithelial malignancies. Cancer Chemother Pharmacol 2012; 69:309-315
9. Palmieri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M, Montella L, Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Bioi Sci 2007; 12:757-761
10. Rajan A, Giaccone G. Targeted therapy for advanced thymic tumors. J Thorac Oncol 2010; 5:S361-S364
11. Gabardi S, Baroletti SA. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 2010; 30:1044-1056
12. Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, Loehrer PJ. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 2011; 29:2060-2065
13. Giaccone G, Ardizzone A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996; 14:814-820
14. Loehrer PJ, Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D, Blum R. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994; 12:1164-1168
15. Loehrer PJ, Yiannoutsos CT, Dropcho S. A phase II trial of pemtrexed in patients with recurrent thymus or thymic carcinoma. J Clin Oncol 2006; 24:7079
16. Palmieri G, Lastoria S, Colao A, Vergara E, Varrella P, Biondi E, Selleri C, Catalano L, Lombardi G, Bianco AR, Salvatore M. Successful treatment of a patient with a thymoma
and pure red-cell aplasia with octreotide and prednisone. *N Engl J Med* 1997; **336**: 263-265

17 **Zucali PA**, Petrini I, Lorenzi E, Merino M, Cao L, Di Tommaso L, Lee HS, Incarbone M, Walter BA, Simonelli M, Roncalli M, Santoro A, Giaccone G. Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. *Cancer* 2010; **116**: 4686-4695

18 **Yoh K**, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H, Niho S, Nagai K, Saijo N. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. *Lung Cancer* 2008; **62**: 316-320

19 **Naing A**, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. *Clin Cancer Res* 2011; **17**: 6052-6060

20 **Seki Y**, Yamamoto N, Tamura Y, Goto Y, Shibata T, Tanioka M, Asahina H, Nokihara H, Yamada Y, Shimamoto T, Noguchi K, Tamura T. Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. *Cancer Chemother Pharmacol* 2012; **69**: 1099-1105

S- Editor Yang XC  L- Editor A  E- Editor Yang XC